liz ann sonders, charles schwab chief investment strategist, joining us now. obviously, the vaccine rollout going a lot better in the u.s. and the u.k. then it is in europe. how do you think about allocating regionally, given the divergence we have seen in the way that program is going? liz ann: it is not only because of vaccine. in fact, i would suggest it is maybe a small part of it. we went to an overweight non-us, or international stocks, at the beginning of this year. the offset to that from a tactical perspective was a downgrade of u.s. large caps. so we now favor small caps in the u.s. a bit more than large caps, but broadly in terms of global equities, we have a bias towards developed international equities. the primary reason, in addition to things like vaccine and more reasonable valuations, is that we believe when you exit one full cycle, a psycho inclusive of a bear market and a recession, you tend to see a shift in leadership patterns. you tend to go to eight to 10 year periods where you flip u.s. to non-us in terms of equities. we think we are at